Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001950099 | SCV002201131 | uncertain significance | Biotinidase deficiency | 2021-08-26 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with methionine at codon 37 of the BTD protein (p.Val37Met). The valine residue is weakly conserved and there is a small physicochemical difference between valine and methionine. This variant is present in population databases (rs772369148, ExAC 0.06%). This variant has not been reported in the literature in individuals affected with BTD-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001950099 | SCV002777370 | uncertain significance | Biotinidase deficiency | 2021-08-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002561398 | SCV003753474 | uncertain significance | Inborn genetic diseases | 2021-09-16 | criteria provided, single submitter | clinical testing | The c.109G>A (p.V37M) alteration is located in exon 2 (coding exon 2) of the BTD gene. This alteration results from a G to A substitution at nucleotide position 109, causing the valine (V) at amino acid position 37 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |